Playback speed
10 seconds
ASCO 2022 on RELATIVITY-047 Trial: Nivolumab + Relatlimab vs. Nivo in 1L Metastatic/Unresectable Melanoma: OS & ORR by Key Subgroups
By
ASCO 2022 Conference Coverage
FEATURING
Piotr Rutkowski
By
ASCO 2022 Conference Coverage
FEATURING
Piotr Rutkowski
1,096 views
June 9, 2022
Login to view comments.
Click here to Login